Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Hisamitsu Pharmaceutical Co's average EPS without NRI Growth Rate was 10.50% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 22.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 21.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Hisamitsu Pharmaceutical Co was 28.60% per year. The lowest was -21.70% per year. And the median was 1.70% per year.
Hisamitsu Pharmaceutical Co (FSE:4530) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Hisamitsu Pharmaceutical Co 3-Year EPS without NRI Growth Rate Related Terms
FSE:4530 vs AMPH, ESPR, NIKA: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's 3-Year EPS without NRI Growth Rate falls into.
Hisamitsu Pharmaceutical Co 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 22.70% mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a 3-Year EPS without NRI Growth Rate of 22.70% as of Nov. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Hisamitsu Pharmaceutical Co and its competitors. This is 1235% above median its historical median of 1.70.
Is Hisamitsu Pharmaceutical Co's 3-Year EPS without NRI Growth Rate too high?
Hisamitsu Pharmaceutical Co's current 3-Year EPS without NRI Growth Rate of 22.70% is 1235% above median its 10-year median of 1.70. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.80. Hisamitsu Pharmaceutical Co's value of 22.70% is 131.6% above this industry median. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's 3-Year EPS without NRI Growth Rate compare to AMPH and ESPR?
Hisamitsu Pharmaceutical Co's 3-Year EPS without NRI Growth Rate of 22.70% can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year EPS without NRI Growth Rate is 9.80. Hisamitsu Pharmaceutical Co's value of 22.70% is 131.6% above this benchmark. While the company's 10-year median is 1.70 vs. the industry median of 9.80, Hisamitsu Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 783 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current 3-Year EPS without NRI Growth Rate of 22.70% is 131.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current 3-Year EPS without NRI Growth Rate is 22.70%, which is 1235% above median its own 10-year median of 1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current 3-Year EPS without NRI Growth Rate of 22.70%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 22.70%, which is 1235% above median its 10-year median of 1.70 and 131.6% above the Drug Manufacturers industry median of 9.80. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current 3-Year EPS without NRI Growth Rate is 22.70% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
3-Year EPS without NRI Growth Rate: 22.70% (1235% above median its 10-year median of 1.70)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 131.6% above the Drug Manufacturers median
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
